Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential.

Aurora Investment Counsel acquired a new stake in Haemonetics Corporation (NYSE: HAE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,501 shares of the medical instruments supplier's stock, valued at approximately $1,913,000. Aurora Investment Counsel owned about 0.06% of Haemonetics as

On August 18, 2026, Haemonetics Corp (HAE) shares rose 15.9%, bringing the current price to $104.65. This performance reflects a significant 52-week range, with

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.

Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Haemonetics NYSE: HAE reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The company raised its full-year revenue outlook, citing broad-based growth across its MedSurg and apheresis businesses, while maintaining a disciplined stance on assumptions for the remainder of the year.

Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript

Haemonetics (HAE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.1 per share a year ago.